Coloplast A/S ((GB:0QBO)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Coloplast A/S is conducting a clinical study titled ‘Feasibility of a Newly Developed Ostomy Prototype’ to address leakage issues faced by individuals with ileostomy. The study aims to test a new leakage measurement device designed to improve the quality of life for stoma patients by reducing leakage problems.
The intervention being tested is a device named CP369, a newly developed ostomy prototype. This device is intended to measure and potentially reduce leakage around stomas, thereby enhancing patient comfort and confidence.
The study is designed as an open-label, single-arm trial, where participants serve as their own controls. There is no masking involved, and the primary purpose is to assess the feasibility of the device.
The study is set to begin on July 25, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on August 27, 2025, indicating the study is in its initial stages.
This development could positively impact Coloplast’s stock performance by showcasing innovation in addressing common patient concerns, potentially setting the company apart from competitors in the medical device industry.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.